Persistence of anti-HBs antibodies at Month 24, 30 and 36 in subjects who had completed primary vaccination was evaluated. The anamnestic response to a booster dose was evaluated in subjects with anti-HBs antibody titres \< 10 mIU/ml at previous timepoint. The study also evaluated the effect of a booster dose of the vaccine (Month 42) after primary vaccination.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
120
GSK Investigational Site
Hradec Králové, Czechia
GSK Investigational Site
Bandar Tun Razak, Cheras, Malaysia
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Anti-HBs seroprotection
Response to booster
Solicited, unsolicited symptoms and serious adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Málaga, Spain